ChiCTR2400090516 版本V1.0 版本创建时间2024/10/08 09:23:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400090516 

最近更新日期:

Date of Last Refreshed on:

2024-10-08 09:22:27 

注册时间:

Date of Registration:

2024-10-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

小剂量艾司氯胺酮对胸科无管化麻醉患者术后痛觉过敏和早期恢复质量的影响

Public title:

Effect of low dose esketamine on postoperative hyperalgesia and early recovery quality in patients undergoing non-intubated thoracoscopic surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

小剂量艾司氯胺酮对胸科无管化麻醉患者术后痛觉过敏和早期恢复质量的影响

Scientific title:

Effect of low dose esketamine on postoperative hyperalgesia and early recovery quality in patients undergoing non-intubated thoracoscopic surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张容波 

研究负责人:

张容波 

Applicant:

Rongbo Zhang 

Study leader:

Rongbo Zhang 

申请注册联系人电话:

Applicant telephone:

+86 13983818540

研究负责人电话:

Study leader's
telephone:

+86 13983818540

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

650243@hospital.cqmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

650243@hospital.cqmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝北区回兴街道双湖支路1号

研究负责人通讯地址:

重庆市渝北区回兴街道双湖支路1号

Applicant address:

No. 1, Shuanghu Branch Road, Huixing Street, Yubei District, Chongqing

Study leader's address:

No. 1, Shuanghu Branch Road, Huixing Street, Yubei District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第三医院

Affiliation of the Leader:

The Third Affiliated Hosptial of ChongQing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年科伦第(51)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第三医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Third Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-08 00:00:00

伦理委员会联系人:

陈帅

Contact Name of the ethic committee:

Chen Shuai

伦理委员会联系地址:

重庆市渝北区双湖支路1号

Contact Address of the ethic committee:

No1 Shuanghu Branch Road Yubei District Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 67167736

伦理委员会联系人邮箱:

Contact email of the ethic committee:

735200243@qq.com

研究实施负责(组长)单位:

重庆医科大学附属第三医院

Primary sponsor:

The Third Affiliated Hosptial of ChongQing Medical University

研究实施负责(组长)单位地址:

重庆市渝北区双湖支路1号

Primary sponsor's address:

No1 Shuanghu Branch Road Yubei District Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第三医院

具体地址:

重庆市渝北区双湖支路1号

Institution
hospital:

The Third Affiliated Hosptial of ChongQing Medical University

Address:

No1 Shuanghu Branch Road Yubei District Chongqing

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-financing

研究疾病:

肺结节、肺大疱  

Target disease:

Pulmonary nodules and bullae

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

IV期临床试验 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

明确小剂量的艾司氯胺酮对胸科无管化麻醉患者术后痛觉过敏和早期恢复质量的影响;探究小剂量的艾司氯胺酮是否有助于非插管电视胸腔镜手术(NIVATS)的麻醉管理;是否能减少术中阿片类药物的消耗,减少术后镇痛补救,降低术后并发症的发生。  

Objectives of Study:

To determine effect of low dose esketamine on postoperative hyperalgesia and early recovery quality in patients undergoing non-intubated thoracoscopic surgery. To explore whether low dose esketamine is helpful for anesthesia management in non-intubation video-assisted thoracoscopic surgery (NIVATS). Whether it can reduce intraoperative and postoperative opioid consumption, reduce postoperative analgesia remedies, and reduce the occurrence of postoperative complications.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.拟行单孔VATS手术治疗,预计手术时间<3h;(2)性别不限,年龄18~65岁;(3)ASA分级Ⅰ-Ⅱ级;(4)18.0kg/m2≦BMI≦25.0kg/m2;(5)心肺及其他重要脏器功能基本正常,可耐受手术;(6)既往无胸部手术史;(7)患者自愿使用静脉自控镇痛(PCIA);(8)患者自愿参加此次研究。

Inclusion criteria

1. Single-port VATS surgery is planned, and the estimated operation time is < 3h;
2.(2) Gender is not limited, age 18-65 years old;
3.(3) ASA grade I-II;
4.(4) 18.0kg/m2≦BMI≦25.0kg/m2;
5.(5) The function of heart, lung and other important organs is basically normal and can tolerate surgery;
6.(6) No previous history of thoracic surgery;
7.(7) Patients voluntarily used controlled intravenous analgesia (PCIA);
8.(8) Patients volunteered to participate in this study.

排除标准:

1.气管解剖异常;(2)有困难插管史、慢性呼吸系统疾病及呼吸睡眠暂停综合征病史;(3)营养状况差,体重指数(BMI)<18.0 kg/m2,血白蛋白<30g/L,血红蛋白<100 g/L;(4)BMI>25.0 kg/m2;(5)患有精神类疾病等无法配合者;(6)肺外器官转移者;(7)合并其他严重疾病者;(8)长期应用镇痛药物者;(9)治疗后控制不良的高血压病史;(10)眼压及颅内压增高、(11)甲亢;(12)严重凝血功能障碍;(13)严重过敏等。

Exclusion criteria:

1. Abnormal trachea anatomy;
2.(2) History of difficult intubation, chronic respiratory diseases and apnea syndrome;
3.(3) Poor nutritional status, body mass index (BMI) < 18.0kg/m2, blood albumin < 30g/L, hemoglobin < 100g/L;
4.(4)BMI > 25.0kg/m2;
5.(5) Those who are unable to cooperate with mental illness;
6.(6) Patients with extrapulmonary organ metastasis;
7.(7) Patients with other serious diseases;
8.(8) long-term use of analgesic drugs;
9.(9) A history of poorly controlled hypertension after treatment;
10.(10) Increased intraocular pressure and intracranial pressure, (11) hyperthyroidism;
11.(12) severe coagulation dysfunction;
12.(13) Severe allergies, etc.

研究实施时间:

Study execute time:

From 2024-10-10 00:00:00 To 2025-02-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-10-10 00:00:00 To 2025-02-10 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

41

Group:

Experimental group

Sample size:

干预措施:

诱导前5min,静脉给予0.25mg/kg艾司氯胺酮,插入喉罩后再以0.15mg/kg?h维持到缝皮时结束。

干预措施代码:

Intervention:

Esmketamine 0.25mg/kg was administered intravenously 5min before induction, and then 0.15mg/kg?h was maintained until skin suture.

Intervention code:

组别:

对照组

样本量:

41

Group:

Control group

Sample size:

干预措施:

等量的0.9%生理盐水

干预措施代码:

Intervention:

The same amount of 0.9% saline

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第三医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hosptial of ChongQing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

中枢、外周痛觉敏化程度

指标类型:

主要指标

Outcome:

Degree of central and peripheral pain sensitization

Type:

Primary indicator

测量时间点:

T0(术前)、T1(术后30min)、T2(术后6h)、T3(术后24h)、T4(术后48h)

测量方法:

分别对患者在不同时间点分别测量左前臂(非优势前臂)内侧肘关节折痕前3、5、7cm皮肤处测量痛阈值取平均值,切口旁左、右、上5cm皮肤处测量痛阈值取平均值。

Measure time point of outcome:

before surgery,30min after surgery, 6h after surgery, ,24h after surgery, 48h after surgery

Measure method:

Average pain thresholds were measured at 3, 5, and 7cm before the crease of the medial elbow joint of the left forearm (non-dominant forearm) at different time points, and average pain thresholds were measured at left, right, and 5cm above the incision.

指标中文名:

早期恢复质量

指标类型:

次要指标

Outcome:

Early recovery quality

Type:

Secondary indicator

测量时间点:

术后1天,术后3天

测量方法:

应用40项恢复质量量表(QoR-40)评价患者恢复质量。

Measure time point of outcome:

1 day after surgery,3 day after surgery

Measure method:

The 40-item Quality of Recovery Scale (QoR-40) was used to evaluate the recovery quality of patients.

指标中文名:

匹兹堡睡眠质量指数(PSQI)

指标类型:

次要指标

Outcome:

Pittsburgh Sleep Quality Index (PSQI)

Type:

Secondary indicator

测量时间点:

术前1天、术后1天、术后3天

测量方法:

采用PSQI评价患者术后睡眠质量。

Measure time point of outcome:

1 day before surgery and 1 day after surgery and 3 days after surgery

Measure method:

The sleep quality was evaluated by PSQI.

指标中文名:

术中生命体征

指标类型:

次要指标

Outcome:

Intraoperative vital signs

Type:

Secondary indicator

测量时间点:

术中

测量方法:

术中观察

Measure time point of outcome:

During operation

Measure method:

Intraoperative observation

指标中文名:

拔出喉罩时间

指标类型:

次要指标

Outcome:

Time to remove laryngeal mask

Type:

Secondary indicator

测量时间点:

术后复苏期

测量方法:

观察记录

Measure time point of outcome:

Postoperative recovery period

Measure method:

Observation record

指标中文名:

PACU停留时间

指标类型:

次要指标

Outcome:

PACU stay time

Type:

Secondary indicator

测量时间点:

术后恢复期

测量方法:

观察记录

Measure time point of outcome:

Postoperative recovery period

Measure method:

Observation record

指标中文名:

PCIA首次按压时间

指标类型:

次要指标

Outcome:

PCIA first press time

Type:

Secondary indicator

测量时间点:

术后

测量方法:

通过PCIA数据系统反馈

Measure time point of outcome:

Postoperative

Measure method:

Feedback via PCIA data system

指标中文名:

PCIA按压次数和有效按压次数

指标类型:

次要指标

Outcome:

Times of PCIA device pressing and effective compressing

Type:

Secondary indicator

测量时间点:

术后

测量方法:

通过PCIA数据系统反馈

Measure time point of outcome:

Postoperative

Measure method:

Feedback via PCIA data system

指标中文名:

NRS评分

指标类型:

次要指标

Outcome:

NRS score

Type:

Secondary indicator

测量时间点:

术后30min、术后6h、术后12h、术后24h、术后48h

测量方法:

结合数字评分量表,采用交谈方式获得患者的疼痛评分

Measure time point of outcome:

30min, 6h, 12h, 24h, 48h after surgery

Measure method:

The pain score of the patients was obtained by talking with the numerical rating scale

指标中文名:

术中阿片类药消耗

指标类型:

次要指标

Outcome:

Intraoperative opioid consumption

Type:

Secondary indicator

测量时间点:

术中

测量方法:

术中记录以及微量泵反馈

Measure time point of outcome:

Intraoperative

Measure method:

Intraoperative records and micropump feedback

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

Postoperative complication

Type:

Secondary indicator

测量时间点:

术后

测量方法:

观察记录

Measure time point of outcome:

postoperation

Measure method:

Record by observation

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

项目负责人根据计算机软件获得随机数表

Randomization Procedure (please state who generates the random number sequence and by what method):

The project leader obtains a table of random numbers based on computer software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

自行设计的CRF表格,然后由两名研究者按双录入法录入电脑,建立电子数据库并附有锁定功能。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The CRF form was designed by oneself and then entered into the computer by two researchers according to the double entry method to establish an electronic database with locking function.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-10-08 09:22:28